CD19 and neoplasm: Weekly blood samples were also analyzed via flow cytometry to examine the number of circulating CD19+ tumor cells (Figure 4F) and CD22-CAR-T cells (Figure 4G), with CAR-T cells expressing 1ug36-sdCAR showing the highest CAR-T expansion in vivo.